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UV detectorAbstract In this study, a simple, precise and accurate reverse phase high performance liquid chro-
matography was developed for the estimation of Erlotinib in bulk and pharmaceutical dosage
forms. A reverse phase Merck C18 column (250 cm · 4.6 mm · 5 lm) with mobile phase consisting
of potassium dihydrogen orthophosphate and acetonitrile (70:30 V/V) having pH 5.0 was adjusted
with orthophosphoric acid was used. The ﬂow rate was 0.8 mL min1 and the efﬂuents were mon-
itored at 246 nm. The retention time was found to be 4.54 min. The linearity of the drug was
obtained in the range of 10–60 lg mL1. The results of analysis have been validated according to
ICH guideline requirements for registration of human use.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Erlotinib, N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)-4-
quinazolinamine (Fig. 1), is a new drug for the treatment of
lung cancer. Simultaneous quantiﬁcation of Erlotinib, Geﬁti-
nib and Imatinib in human plasma by liquid chromatography
tandem mass spectrometry, therapeutic drug monitoring(Chahbouni et al., 2009). The mechanism of action involved
is an epidermal growth factor receptor inhibitor. It speciﬁcally
targets the epidermal growth factor receptor (EGFR) tyrosine
kinase, which is highly expressed and occasionally mutated in
various forms of cancer. It binds in a reversible fashion to the
adenosine triphosphate (ATP) binding site of the receptor. For
the signal to be transmitted, two members of the EGFR family
need to come together to form a homo dimer. These then use
the molecule of ATP to autophosphorylate each other, which
causes a conformational change in their intracellular structure,
exposing a further binding site for binding proteins that cause
a signal cascade to the nucleus. By inhibiting the ATP, auto-
phosphorylation is not possible and the signal is stopped.
It is not ofﬁcial in any Pharmacopoeia and was approved
by FDA as monotherapy for the treatment of patients with
locally advanced or metastatic non-small cell lung cancer
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Figure 1 Chemical structure of Erlotinib.
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tablet is available in the market with the brand name of Erlo-
cip (Cipla), Tarceva (Roche) and Erloshil (Raichem). A few
analytical methods have been reported for quantitative estima-
tion of Erlotinib in pharmaceutical formulations. Simple and
selective method for the determination of various tyrosine ki-
nase inhibitors used in the clinical setting by LC-MS (Honey-
well et al., 2010). Development and validation of the UV
Spectrophotometric method for the determination of Erlotinib
in tablet formulation (Padmalatha et al., 2011). Spectrophoto-
metric method for the determination of Erlotinib in pure and
pharmaceutical dosage form Padmalatha et al. (2011a).
Development and validation of high performance liquid
chromatographic method for the determination of Erlotinib
(Padmalatha et al., 2011b). Spectroscopic studies on the inter-
action between Erlotinib hydrochloride and bovine serum
albumin (Rasoulzadeh et al., 2010). Extractive colorimetric
method development and validation for Erlotinib in bulk
and tablet dosage form (Usha Rani et al., 2011).
2. Experimental procedure
2.1. Instruments
HPLC system (water’s 2695 Milford, USA) equipped with
auto sampler and gradient pump with degasser was used.
The column component having temperature control, UV
detector (2489) was employed throughout the analysis. Chro-
matographic data were acquired by using empower software
2. Analytical balance (Sartorius, BSA 2245-CN) and Merck
C18 column ((250 cm · 4.6 mm · 5 lm) were used.200.0 220 240 260 280 30
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Figure 2 kmax2.2. Reagents and chemicals
All reagents and solvents were of analytical and HPLC grade
including acetonitrile, sodium dihydrogenphosphate, ortho-
phosphoric acid and monobasic sodium phosphate purchased
from Sd ﬁne-chem Ltd., Mumbai, India. High purity deionized
water was obtained by double distillation and puriﬁcation
through milli-Q water puriﬁcation system. The 0.45 lm nylon
ﬁlter was purchased from advanced micro device Pvt Ltd.,
Chandigarh.
2.3. Buffer preparation
Potassium dihydrogen orthophosphate (2.72 g) was dissolved
in 100 mL of HPLC grade water and pH 5.0 was adjusted with
orthophosphoric acid. It was ﬁltered through 0.45 lm nylon
membrane ﬁlter and degassed. It was used as a diluent for
the preparation of sample and standard solution.
3. Method
3.1. Selection of wavelength
Accurately weighed quantity of the sample equivalent to 50 mg
of Erlotinib was taken in a 50 mL volumetric ﬂask. 25 mL of
methanol was added, sonicated for 10 min and ﬁltered through
0.45 lm nylon ﬁlter. The above solution was scanned between
200 and 400 nm by UV spectroscopy (Fig. 2).
3.2. Chromatographic conditions
The experiments were performed with isocratic elution. The
binary mobile phase consisted of a mixture of Potassium
dihydrogen Phosphate buffer (0.02 M) and acetonitrile in
the ratio of 70:30 V/V. The pH 5.0 was adjusted by using
0.1% orthophosphoric acid which was ﬁltered through a
membrane ﬁlter. The efﬂuents were degassed before running
at a ﬂow rate of 0.8 mL min1. The column temperature
was ambient at 27 C. The 20 lL volume of sample was in-
jected per run and efﬂuents were detected using UV detector
at k= 246 nm.0 320 340 360 380 400.0
m
333.02
of Erlotinib.
Figure 3 Chromatogram for Standard.
Figure 4 Linearity graph.
Table 1 Regression characteristics, validation and system
suitability for the analysis of Erlotinib.
Parameters
System suitability
Retention time (min) 4.54
Theoretical plate count 6470
Tailing factor 1.147
Linearity range (lg mL1) 10–60
Detection limit (lg mL1) 0.62
Quantitation limit (lg mL1) 2.07
Regression date
Slope 38.56
Intercept 77.41
Correlation coeﬃcient 0.999
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Standard stock solution of Erlotinib of 1000 lg mL1 was pre-
pared by dissolving 25 mg of standard drug in 20 mL of diluent
in a 25 mL volumetric ﬂask. The above solution was sonicated
for 10 min and the volume was made with the same diluent.
0.5 mL of the standard stock solution was diluted to 10 mLwith
the same diluent to get the ﬁnal concentration of 500 lg mL1.
The chromatogram of the standard is shown in Fig. 3.To study the linearity of the drug, the serial dilution of
standard stock solution was made in the range of 10–
60 lg mL1. A graph was plotted as concentration of drug
versus peak area response. It was found to be linear for
the given concentration of the drug (Fig. 4 and Table 1).
3.4. Sample solution
Twenty tablets (Erlonat and Tarceva) of each containing
150 mg of Erlotinib were accurately weighed, averaged and ﬁ-
nely powdered. A quantity of powder equivalent to the weight
of one tablet was weighted and transferred to a 100 mL volu-
metric ﬂask and 70 mL of diluent was added. The volumetric
ﬂask was sonicated for 10 min to complete dissolution of the
drug in the solution, ﬁltered through a 0.45 lm nylon ﬁlter
and made up to the volume with diluent. 5 mL of the ﬁltrate
was taken in a 100 mL volumetric ﬂask and made up to the
volume with same diluent to the ﬁnal concentration of
150 lg mL1 (Fig. 5 and Table 2).
3.5. Evaluation of system suitability
System suitability was studied under each validation parameter
by injecting six replicate injections of the standard solution
(10 lg mL1). System suitability parameters like column efﬁ-
ciency, plate count and tailing factor were recorded. The re-
sults obtained were within the limit and is shown in the
Table 1. The % RSD of six injections of standard solution is
not more than 2%.
4. Analytical method validation
4.1. Precision
The system precision was demonstrated by preparing the stan-
dard solution at test concentration and injected repeatedly for
six times. The % RSD for repeatability of standard prepara-
tion is 0.029, whereas % RSD for repeatability of sample prep-
aration is 0.017. The method precision is satisfactory and the
% RSD is not more than 2.0%. The results are shown in Ta-
ble 3 and Fig. 6.
Figure 5 Chromatogram for sample.
Table 3 Precision study.
S. No. System precision Method precision
Rt AUC Rt AUC
1 4.547 2001.342 4.533 2023.103
2 4.553 1998.325 4.530 2008.643
3 4.530 1988.298 4.533 2016.470
4 4.550 1990.750 4.543 2012.385
5 4.547 1985.649 4.553 2019.930
Mean 4.5454 1992.873 4.5384 2016.106
SD 0.008961 6.690893 0.009529 5.771821
% RSD 0.197145 0.335741 0.209962 0.286286
Figure 6 Chromatogram for precision.
Table 4 Intermediate precision.
S. No. Analyst 1 Analyst 2
1 1.2038 1.2042
2 1.2035 1.2044
3 1.2039 1.2049
Mean 1.203733 1.2045
SD 0.000208 0.000361
% RSD 0.017293 0.029934
Table 2 Analysis of marketed formulations.
Commercial
formulation
(tablet)
Ingredients Labeled
amount
(mg)
Amount
found
(mg) n= 6
Found
%
Erlonat (Natco) Erlotinib 150 149.38 99.58
Tarceva (Roche) Erlotinib 150 149.13 99.42
Table 5 Accuracy study.
Level % Amount added
(lg mL1)
Mean
(n= 6)
% Recovery Mean %
recovery
80 5 1885.624 101.97 101.97
100 5 2253.959 99.72 99.72
120 5 2636.167 98.69 98.69
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Intermediate precision of the method was determined by ana-
lyzing the standard solution with two analysts using differentinstruments in different labs and on different days. The %
RSD obtained under different conditions were found to be less
than 2.0% (Table 4).
4.3. Recovery studies
To ascertain the accuracy of the method, recovery studies were
carried out in triplicate by spiking different concentrations of
pure drug in the pre analyzed samples with three different con-
centrations of standard containing 80%, 100% and 120% of
the pure drug. The mean recovery percentage obtained was
100.12% for the assay. FDA approval for Erlotinib is 97–
103%. The data are shown in the Table 5.
4.4. Robustness
Robustness of the method was determined by deliberately
changing some operating conditions such as ﬂow rate and
wavelength. It was observed that there were no remarkable
changes in chromatogram, the tailing factor and plate counts.
Hence the robustness of the method is established to the extent
of variations applied to analytical conditions. The results are
shown in Table 6 and Figs. 7–10.
4.5. Limit of detection
Limit of detection can be calculated using the following equa-
tion according to ICH guidelines:
LOD= 3.3 · N/S where N is the standard deviation of
peak areas of the drug and S is the slope of the corresponding
calibration curve. The results are shown in Table 1.
4.6. Limit of quantiﬁcation
Limit of quantiﬁcation can be calculated using the following
equation according to ICH guidelines:
LOQ= 10 · N/S where N is the standard deviation of peak
areas of the drug and S is the slope of the corresponding cal-
ibration curve. The results are shown in Table 1.
Table 6 Robustness study.
Flow rate (mL1) Wavelength (nm)
0.6 1 244 248
Peak area Tailing factor Peak area Tailing factor Peak area Tailing factor Peak area Tailing factor
2059.971 1.114 2053.141 1.152 2053.727 1.167 2089.011 1.118
2059.093 1.126 2057.702 1.147 2051.059 1.175 2092.556 1.114
2058.948 1.109 2058.598 1.158 2056.952 1.161 2093.893 1.121
Mean 2059.33 2056.48 2053.91 2091.82
SD 0.553 2.926 2.950 2.522
% RSD 0.026 0.142 0.143 0.120
Figure 7 Chromatogram for robustness (change in wavelength).
Figure 8 Chromatogram for robustness (change in wavelength).
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Chromatographic parameters were optimized to develop a
HPLC method for the determination of Erlotinib with short
analysis time (<5 min) and acceptable resolution (Rs > 2).
Various compositions of mobile phase like water:methanol
(65:35 V/V), buffer:methanol (30:70 V/V) and phosphate
buffer:acetonitrile (70:30 V/V) in different ratios were triedat a ﬂow rate of 0.8 mL min1. Phosphate buffer pH 5.0 and
acetonitrile showed symmetrical peaks with good resolution.
The optimum wavelength for detection was 246 nm and the
retention time was found to be 4.54 min.
Linear curve was obtained in the concentration range of
10–60 lg mL1. LOD and LOQ were determined from the
slope and standard deviation of Y-intercept of the regression
line of the calibration curve. It was found to be 6.62 and
Figure 10 Chromatogram for robustness (change in ﬂow rate).
Figure 9 Chromatogram for robustness (change in ﬂow rate).
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instrument precision were evaluated and the % RSD values
were less than 2.0%. The accuracy of the method was deter-
mined by recovery studies. The recovery studies were close to
100% which complies with FDA approval of the drug.
Developed method was found to be robust while changing
the ﬂow rate, wavelength detection, temperature and compo-
sition of mobile. There was no considerable change in the
peak areas and retention time. The parameters like tailing
factor and retention time showed adherence to the limit.
The proposed method is superior when compared to the
reported method with less retention time, high theoretical
plate count and composition of the mobile phase with good
separation.
6. Conclusion
The method developed for Erlotinib was found to be simple,
precise, sensitive, rapid, robust and economical. The analytical
conditions developed with good resolution within a short anal-
ysis time. The % RSD for all parameters was found to be with-
in the limit. This indicates the result and assay obtained by thismethod are in good agreement. Thus the method developed
can be used for the routine analysis of Erlotinib in laboratories
and quality control purpose.
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